Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology - PubMed (original) (raw)
Clinical Trial
. 1991 Jun 29;337(8757):1555-7.
- PMID: 1675705
Clinical Trial
Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology
No authors listed. Lancet. 1991.
Abstract
In children with corticosteroid-responsive nephrotic syndrome who are dependent on high-dose prednisolone, alkylating therapy often fails to maintain a remission, and long-term immunosuppression may be hazardous. An alternative approach to treatment is to use an immunostimulant such as levamisole. 61 children with frequently relapsing corticosteroid sensitive and dependent nephrotic syndrome were randomly allocated to receive levamisole, 2.5 mg/kg on alternate days (31 patients) or placebo (30 patients) for a maximum of 112 days. After entry to the trial, prednisolone was progressively reduced and was stopped by 56 days. The two groups were well matched for age and sex distribution, indices of corticosteroid toxicity, and previous alkylating therapy. 14 patients in the levamisole group and 4 in the placebo group remained in remission at 112 days (log rank analysis p less than 0.01). No significant adverse events were recorded. Levamisole is effective in maintaining a steroid-free remission in this condition and has few side-effects.
Comment in
- Levamisole in nephrotic syndrome.
Srivastava RN, Vasudev AS, Bagga A. Srivastava RN, et al. Lancet. 1991 Nov 16;338(8777):1275. doi: 10.1016/0140-6736(91)92143-p. Lancet. 1991. PMID: 1682671 Clinical Trial. No abstract available.
Similar articles
- Efficacy of higher-dose levamisole in maintaining remission in steroid-dependant nephrotic syndrome.
Abeyagunawardena AS, Karunadasa U, Jayaweera H, Thalgahagoda S, Tennakoon S, Abeyagunawardena S. Abeyagunawardena AS, et al. Pediatr Nephrol. 2017 Aug;32(8):1363-1367. doi: 10.1007/s00467-017-3616-5. Epub 2017 Mar 15. Pediatr Nephrol. 2017. PMID: 28299461 Clinical Trial. - Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study).
Veltkamp F, Khan DH, Reefman C, Veissi S, van Oers HA, Levtchenko E, Mathôt RAA, Florquin S, van Wijk JAE, Schreuder MF, Haverman L, Bouts AHM. Veltkamp F, et al. BMJ Open. 2019 Aug 1;9(8):e027011. doi: 10.1136/bmjopen-2018-027011. BMJ Open. 2019. PMID: 31375606 Free PMC article. - Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children.
Donia AF, Amer GM, Ahmed HA, Gazareen SH, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA. Donia AF, et al. Pediatr Nephrol. 2002 May;17(5):355-8. doi: 10.1007/s00467-001-0813-y. Pediatr Nephrol. 2002. PMID: 12042893 - Management strategy for idiopathic nehprotic syndrome in children.
Chiu MC. Chiu MC. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008 Jan;33(1):1-7. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008. PMID: 18245896 Review. - Management of steroid sensitive nephrotic syndrome: revised guidelines.
Indian Pediatric Nephrology Group, Indian Academy of Pediatrics; Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, Senguttuvan P, Sethi S, Shah M. Indian Pediatric Nephrology Group, Indian Academy of Pediatrics, et al. Indian Pediatr. 2008 Mar;45(3):203-14. Indian Pediatr. 2008. PMID: 18367765 Review.
Cited by
- Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Larkins NG, Hahn D, Liu ID, Willis NS, Craig JC, Hodson EM. Larkins NG, et al. Cochrane Database Syst Rev. 2024 Nov 8;11(11):CD002290. doi: 10.1002/14651858.CD002290.pub6. Cochrane Database Syst Rev. 2024. PMID: 39513526 Review. - Levamisole Induced Agranulocytosis in a Child with Steroid Dependent Nephrotic Syndrome: A Case Report.
Anjum MF, Gupta GK, Bhandari J. Anjum MF, et al. JNMA J Nepal Med Assoc. 2024 Jul 31;62(276):545-547. doi: 10.31729/jnma.8700. JNMA J Nepal Med Assoc. 2024. PMID: 39369404 Free PMC article. - Efficacy and safety of levamisole in childhood nephrotic syndrome: A meta-analysis.
Bhatt GC, Patel B, Das RR, Malik S, Bitzan M, Mishra NR. Bhatt GC, et al. Indian J Pharmacol. 2023 Jan-Feb;55(1):43-52. doi: 10.4103/ijp.ijp_673_21. Indian J Pharmacol. 2023. PMID: 36960520 Free PMC article. Review. - Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy -short version of the updated German best practice guideline (S2e) - AWMF register no. 166-001, 6/2020.
Ehren R, Benz MR, Brinkkötter PT, Dötsch J, Eberl WR, Gellermann J, Hoyer PF, Jordans I, Kamrath C, Kemper MJ, Latta K, Müller D, Oh J, Tönshoff B, Weber S, Weber LT; German Society for Pediatric Nephrology. Ehren R, et al. Pediatr Nephrol. 2021 Oct;36(10):2971-2985. doi: 10.1007/s00467-021-05135-3. Epub 2021 Jun 6. Pediatr Nephrol. 2021. PMID: 34091756 Free PMC article. Review. - Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM. Larkins NG, et al. Cochrane Database Syst Rev. 2020 Apr 16;4(4):CD002290. doi: 10.1002/14651858.CD002290.pub5. Cochrane Database Syst Rev. 2020. PMID: 32297308 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical